
Anchiano starts Codex study for bladder cancer drug
Anchiano Therapeutics has commenced the Codex, a Phase ll trial examining the efficacy and safety of inodiftagene vixteplasmid (BC-819) for…
Anchiano Therapeutics has commenced the Codex, a Phase ll trial examining the efficacy and safety of inodiftagene vixteplasmid (BC-819) for…
Thank you for subscribing to Clinical Trials Arena